Biased Diversity for Effective Virtual Screening
Overview
Medical Informatics
Authors
Affiliations
Virtual screening is no longer merely a matter of identifying the subset of compounds from a large collection likely to be active against a particular endpoint. This viewpoint shares some distinctive practices at Novartis, where virtual screening combines multiple computational tools that marry the competing goals of biasing the selection of compounds toward multiple desired properties, while diversifying the selection to sample the available chemistry space, identifying quality compounds that inform drug discovery. Topics include the various considerations needed for a successful virtual screening practice: triaging, compound quality, accuracy and test sets, activity prediction including multitask modeling, virtual profiling, automation, multiproperty bias, diversity and property spaces, and biased-diversity designs.
Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace.
Singh N, Chaput L, Villoutreix B Brief Bioinform. 2020; 22(2):1790-1818.
PMID: 32187356 PMC: 7986591. DOI: 10.1093/bib/bbaa034.